Chronic Heart Failure - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：140頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Chronic Heart Failure - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Chronic Heart Failure - Pipeline Review, H1 2014’, provides an overview of the Chronic Heart Failure’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Heart Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Chronic Heart Failure - Pipeline Review, H1 2014’, provides an overview of the Chronic Heart Failure’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Heart Failure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Heart Failure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Heart Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Heart Failure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Heart Failure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Heart Failure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chronic Heart Failure Overview 10
Therapeutics Development 11
Pipeline Products for Chronic Heart Failure - Overview 11
Pipeline Products for Chronic Heart Failure - Comparative Analysis 12
Chronic Heart Failure - Therapeutics under Development by Companies 13
Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes 16
Chronic Heart Failure - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Chronic Heart Failure - Products under Development by Companies 21
Chronic Heart Failure - Products under Investigation by Universities/Institutes 22
Chronic Heart Failure - Companies Involved in Therapeutics Development 23
Hospira, Inc. 23
Sanofi 24
Novartis AG 25
Laboratoires Pierre Fabre SA 26
Les Laboratoires Servier SAS 27
Pfizer Inc. 28
Bayer AG 29
Celladon Corporation 30
Mesoblast Limited 31
Palatin Technologies, Inc. 32
MetrioPharm AG 33
Scynexis, Inc. 34
t2cure GmbH 35
Cyano Biotech GmbH 36
NormOxys, Inc. 37
Cardioxyl Pharmaceuticals, Inc. 38
PhaseBio Pharmaceuticals, Inc. 39
miRagen Therapeutics, Inc. 40
Fibrotech Therapeutics Pty. Ltd. 41
Otsuka Holdings Co., Ltd. 42
Provasculon, Inc. 43
Zensun (Shanghai) Sci & Tech Co., Ltd. 44
Chronic Heart Failure - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Target 47
Assessment by Mechanism of Action 50
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
Neucardin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
rivaroxaban - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
(AHU-377 + valsartan) - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CEP-41750 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
aliskiren fumarate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
sildenafil citrate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PL-3994 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CXL-1020 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
tolvaptan - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
somatropin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Neucardin - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
finerenone - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ivabradine - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
F-373280 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
BMCs - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
cenderitide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
OXY-111A - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
MGN-9103 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
MP-2000 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
BR-5489 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule Allosteric Modulators Of SERCA2a - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
FT-011 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
PB-1046 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
SAR-296968 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
PRV-0023 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Cyclophilin Inhibitory Compounds - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
etomoxir - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
PRV-0023 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Microginins ACE Inhibitors- Program - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Vestiras - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Chronic Heart Failure - Recent Pipeline Updates 103
Chronic Heart Failure - Dormant Projects 127
Chronic Heart Failure - Product Development Milestones 128
Featured News & Press Releases 128
Nov 21, 2013: CHMP Adopts Positive Opinion For Servier's Corlentor 128
Oct 31, 2013: FDA Clears Commencement Of Phase III Chronic Heart Failure Trial Using Mesoblast's Proprietary Cells 128
Jun 18, 2013: PhaseBio Expands Clinical Development Of Vasomera For Cardiopulmonary Diseases 129
May 23, 2013: Zensun Announces Positive Clinical Results For Neucardin To Improve Heart Function And Reduce Mortality In Chronic Heart Failure Patients 130
Apr 11, 2013: Cardio3 BioSciences Announces Publication Of Positive Results From Phase II C-CURE Trial In Journal Of American College Of Cardiology 131
Mar 08, 2013: Bayer And Janssen Initiate New Pivotal Phase III Study Of Xarelto In Patients With Chronic Heart Failure And Significant Coronary Artery Disease 132
Mar 08, 2013: Janssen Launches EXPLORER Global Cardiovascular Research Program For Xarelto 133
Jan 22, 2013: Stealth Peptides Reports Successful Clinical Study Of Oral Bendavia 135
Nov 26, 2012: Servier Laboratories's Ivabradine Receives NICE Recommendation For Treatment Of People With Chronic Heart Failure With Systolic Dysfunction 136
Oct 19, 2012: NICE Draft Guidance Recommends Servier Labs' Ivabradine For Treatment Of Chronic Heart Failure 137
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 140
Disclaimer 140
List of Tables
Number of Products under Development for Chronic Heart Failure, H1 2014 11
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Investigation by Universities/Institutes, H1 2014 22
Chronic Heart Failure - Pipeline by Hospira, Inc., H1 2014 23
Chronic Heart Failure - Pipeline by Sanofi, H1 2014 24
Chronic Heart Failure - Pipeline by Novartis AG, H1 2014 25
Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H1 2014 26
Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H1 2014 27
Chronic Heart Failure - Pipeline by Pfizer Inc., H1 2014 28
Chronic Heart Failure - Pipeline by Bayer AG, H1 2014 29
Chronic Heart Failure - Pipeline by Celladon Corporation, H1 2014 30
Chronic Heart Failure - Pipeline by Mesoblast Limited, H1 2014 31
Chronic Heart Failure - Pipeline by Palatin Technologies, Inc., H1 2014 32
Chronic Heart Failure - Pipeline by MetrioPharm AG, H1 2014 33
Chronic Heart Failure - Pipeline by Scynexis, Inc., H1 2014 34
Chronic Heart Failure - Pipeline by t2cure GmbH, H1 2014 35
Chronic Heart Failure - Pipeline by Cyano Biotech GmbH, H1 2014 36
Chronic Heart Failure - Pipeline by NormOxys, Inc., H1 2014 37
Chronic Heart Failure - Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2014 38
Chronic Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014 39
Chronic Heart Failure - Pipeline by miRagen Therapeutics, Inc., H1 2014 40
Chronic Heart Failure - Pipeline by Fibrotech Therapeutics Pty. Ltd., H1 2014 41
Chronic Heart Failure - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 42
Chronic Heart Failure - Pipeline by Provasculon, Inc., H1 2014 43
Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2014 44
Assessment by Monotherapy Products, H1 2014 45
Assessment by Combination Products, H1 2014 46
Number of Products by Stage and Target, H1 2014 49
Number of Products by Stage and Mechanism of Action, H1 2014 52
Number of Products by Stage and Route of Administration, H1 2014 54
Number of Products by Stage and Molecule Type, H1 2014 56
Chronic Heart Failure Therapeutics - Recent Pipeline Updates, H1 2014 103
Chronic Heart Failure - Dormant Projects, H1 2014 127
List of Figures
Number of Products under Development for Chronic Heart Failure, H1 2014 11
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 45
Number of Products by Top 10 Target, H1 2014 47
Number of Products by Stage and Top 10 Target, H1 2014 48
Number of Products by Top 10 Mechanism of Action, H1 2014 50
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 51
Number of Products by Top 10 Route of Administration, H1 2014 53
Number of Products by Stage and Top 10 Route of Administration, H1 2014 54
Number of Products by Top 10 Molecule Type, H1 2014 55
Number of Products by Stage and Top 10 Molecule Type, H1 2014 56
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chronic Heart Failure Overview 10
Therapeutics Development 11
Pipeline Products for Chronic Heart Failure - Overview 11
Pipeline Products for Chronic Heart Failure - Comparative Analysis 12
Chronic Heart Failure - Therapeutics under Development by Companies 13
Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes 16
Chronic Heart Failure - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Chronic Heart Failure - Products under Development by Companies 21
Chronic Heart Failure - Products under Investigation by Universities/Institutes 22
Chronic Heart Failure - Companies Involved in Therapeutics Development 23
Hospira, Inc. 23
Sanofi 24
Novartis AG 25
Laboratoires Pierre Fabre SA 26
Les Laboratoires Servier SAS 27
Pfizer Inc. 28
Bayer AG 29
Celladon Corporation 30
Mesoblast Limited 31
Palatin Technologies, Inc. 32
MetrioPharm AG 33
Scynexis, Inc. 34
t2cure GmbH 35
Cyano Biotech GmbH 36
NormOxys, Inc. 37
Cardioxyl Pharmaceuticals, Inc. 38
PhaseBio Pharmaceuticals, Inc. 39
miRagen Therapeutics, Inc. 40
Fibrotech Therapeutics Pty. Ltd. 41
Otsuka Holdings Co., Ltd. 42
Provasculon, Inc. 43
Zensun (Shanghai) Sci & Tech Co., Ltd. 44
Chronic Heart Failure - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Target 47
Assessment by Mechanism of Action 50
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
Neucardin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
rivaroxaban - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
(AHU-377 + valsartan) - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CEP-41750 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
aliskiren fumarate - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
sildenafil citrate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PL-3994 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CXL-1020 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
tolvaptan - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
somatropin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Neucardin - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
finerenone - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ivabradine - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
F-373280 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
BMCs - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
cenderitide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
OXY-111A - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
MGN-9103 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
MP-2000 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
BR-5489 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Small Molecule Allosteric Modulators Of SERCA2a - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
FT-011 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
PB-1046 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
SAR-296968 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
PRV-0023 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Cyclophilin Inhibitory Compounds - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
etomoxir - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
PRV-0023 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Microginins ACE Inhibitors- Program - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Vestiras - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Chronic Heart Failure - Recent Pipeline Updates 103
Chronic Heart Failure - Dormant Projects 127
Chronic Heart Failure - Product Development Milestones 128
Featured News & Press Releases 128
Nov 21, 2013: CHMP Adopts Positive Opinion For Servier's Corlentor 128
Oct 31, 2013: FDA Clears Commencement Of Phase III Chronic Heart Failure Trial Using Mesoblast's Proprietary Cells 128
Jun 18, 2013: PhaseBio Expands Clinical Development Of Vasomera For Cardiopulmonary Diseases 129
May 23, 2013: Zensun Announces Positive Clinical Results For Neucardin To Improve Heart Function And Reduce Mortality In Chronic Heart Failure Patients 130
Apr 11, 2013: Cardio3 BioSciences Announces Publication Of Positive Results From Phase II C-CURE Trial In Journal Of American College Of Cardiology 131
Mar 08, 2013: Bayer And Janssen Initiate New Pivotal Phase III Study Of Xarelto In Patients With Chronic Heart Failure And Significant Coronary Artery Disease 132
Mar 08, 2013: Janssen Launches EXPLORER Global Cardiovascular Research Program For Xarelto 133
Jan 22, 2013: Stealth Peptides Reports Successful Clinical Study Of Oral Bendavia 135
Nov 26, 2012: Servier Laboratories's Ivabradine Receives NICE Recommendation For Treatment Of People With Chronic Heart Failure With Systolic Dysfunction 136
Oct 19, 2012: NICE Draft Guidance Recommends Servier Labs' Ivabradine For Treatment Of Chronic Heart Failure 137
Appendix 139
Methodology 139
Coverage 139
Secondary Research 139
Primary Research 139
Expert Panel Validation 139
Contact Us 140
Disclaimer 140
List of Tables
Number of Products under Development for Chronic Heart Failure, H1 2014 11
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Comparative Analysis by Unknown Stage Development, H1 2014 20
Products under Development by Companies, H1 2014 21
Products under Investigation by Universities/Institutes, H1 2014 22
Chronic Heart Failure - Pipeline by Hospira, Inc., H1 2014 23
Chronic Heart Failure - Pipeline by Sanofi, H1 2014 24
Chronic Heart Failure - Pipeline by Novartis AG, H1 2014 25
Chronic Heart Failure - Pipeline by Laboratoires Pierre Fabre SA, H1 2014 26
Chronic Heart Failure - Pipeline by Les Laboratoires Servier SAS, H1 2014 27
Chronic Heart Failure - Pipeline by Pfizer Inc., H1 2014 28
Chronic Heart Failure - Pipeline by Bayer AG, H1 2014 29
Chronic Heart Failure - Pipeline by Celladon Corporation, H1 2014 30
Chronic Heart Failure - Pipeline by Mesoblast Limited, H1 2014 31
Chronic Heart Failure - Pipeline by Palatin Technologies, Inc., H1 2014 32
Chronic Heart Failure - Pipeline by MetrioPharm AG, H1 2014 33
Chronic Heart Failure - Pipeline by Scynexis, Inc., H1 2014 34
Chronic Heart Failure - Pipeline by t2cure GmbH, H1 2014 35
Chronic Heart Failure - Pipeline by Cyano Biotech GmbH, H1 2014 36
Chronic Heart Failure - Pipeline by NormOxys, Inc., H1 2014 37
Chronic Heart Failure - Pipeline by Cardioxyl Pharmaceuticals, Inc., H1 2014 38
Chronic Heart Failure - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2014 39
Chronic Heart Failure - Pipeline by miRagen Therapeutics, Inc., H1 2014 40
Chronic Heart Failure - Pipeline by Fibrotech Therapeutics Pty. Ltd., H1 2014 41
Chronic Heart Failure - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 42
Chronic Heart Failure - Pipeline by Provasculon, Inc., H1 2014 43
Chronic Heart Failure - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2014 44
Assessment by Monotherapy Products, H1 2014 45
Assessment by Combination Products, H1 2014 46
Number of Products by Stage and Target, H1 2014 49
Number of Products by Stage and Mechanism of Action, H1 2014 52
Number of Products by Stage and Route of Administration, H1 2014 54
Number of Products by Stage and Molecule Type, H1 2014 56
Chronic Heart Failure Therapeutics - Recent Pipeline Updates, H1 2014 103
Chronic Heart Failure - Dormant Projects, H1 2014 127
List of Figures
Number of Products under Development for Chronic Heart Failure, H1 2014 11
Number of Products under Development for Chronic Heart Failure - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 45
Number of Products by Top 10 Target, H1 2014 47
Number of Products by Stage and Top 10 Target, H1 2014 48
Number of Products by Top 10 Mechanism of Action, H1 2014 50
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 51
Number of Products by Top 10 Route of Administration, H1 2014 53
Number of Products by Stage and Top 10 Route of Administration, H1 2014 54
Number of Products by Top 10 Molecule Type, H1 2014 55
Number of Products by Stage and Top 10 Molecule Type, H1 2014 56
